NCT00376090View on ClinicalTrials.gov

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
HIV Infections
Interventions
BIOLOGICAL

MVA-CMDR

10\^7 PFU IM, 1.0 mL

BIOLOGICAL

Placebo

1.0 mL IM

BIOLOGICAL

MVA-CMDR

10\^6 PFU ID, 0.1 mL

BIOLOGICAL

Placebo

0.1 mL ID

BIOLOGICAL

MVA-CMDR

10\^8 PFU IM, 1.0 mL

BIOLOGICAL

MVA-CMDR

10\^7 PFD ID, 0.1 mL

Trial Locations (1)

20850

US Military HIV Research Program, Rockville

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED

NCT00376090 - Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults | Biotech Hunter | Biotech Hunter